BioMarin Pharmaceutical Inc. (BMRN)
-NasdaqGS 64.01 
0.49(0.76%) May 17, 4:00PM EDT|After Hours
:
64.00 0.01 (0.02%) May 17, 5:30PM EDT
| Prev Close: | 64.50 |
|---|
| Open: | 65.10 |
|---|
| Bid: | 37.01 x 100 |
|---|
| Ask: | 75.00 x 100 |
|---|
| 1y Target Est: | 69.84 |
|---|
| Beta: | 0.76 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 63.30 - 65.30 |
|---|
| 52wk Range: | 34.30 - 71.56 |
|---|
| Volume: | 1,459,698 |
|---|
| Avg Vol (3m): | 1,304,260 |
|---|
| Market Cap: | 8.90B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.05 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- BioMarin Announces BMN-673 Data in Breast and Ovarian Cancers to be Released at ASCOGlobeNewswire(Thu, May 16)
- Biomarin Stock Falls On Unusually High Volume (BMRN)at TheStreet(Thu, May 16)
- A Fundamental, Bottom-Up Approach to Investing in Health Care: Portfolio Manager Finny Kuruvilla Discusses His Strategies with The Wall Street TranscriptWall Street Transcript(Thu, May 16)
- Celgene, Gilead lower after new data published at ASCOat theflyonthewall.com(Thu, May 16)
- 1 Biotech, 1 Financial And 1 Grocery Store With Recent Intensive Insider Sellingat Seeking Alpha(Thu, May 16)
- BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to aEDGAR Online(Thu, May 16)
- BioMarin abstract showed impressive anti-tumor activity, says Leerinktheflyonthewall.com(Thu, May 16)
- 10 ASCO '13 Abstracts You Can Read Right Nowat TheStreet(Wed, May 15)
- BioMarin to Present at the UBS Global Healthcare ConferenceGlobeNewswire(Tue, May 14)
- Biomarin Reaches New 52-Week High (BMRN)at TheStreet(Mon, May 13)
- BioMarin initiated with a Buy at Goldmantheflyonthewall.com(Tue, May 7)
- BIOMARIN PHARMACEUTICAL INC FinancialsEDGAR Online Financials(Fri, May 3)
- Biomarin Stock Hits New 52-Week High (BMRN)at TheStreet(Fri, May 3)
- BioMarin to Present at the Baird Growth Stock ConferenceGlobeNewswire(Thu, May 2)
- BIOMARIN PHARMACEUTICAL INC FinancialsEDGAR Online Financials(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 17.51 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.30 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.29 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | -1.47 |
|---|
Business Summary
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally.
View More